• Home
  • > Media & Investors
  • > Media Relations
  • > Press Releases
  • > Daiichi Sankyo Announces Phase 3 Study Results for Prasugrel Antiplatelet Agent in Thrombotic Stroke Patients

For Immediate Release

2020.07.21

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Sunao Manabe, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Junichi Onuma,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
https://www.daiichisankyo.com

Daiichi Sankyo Announces Phase 3 Study Results for Prasugrel Antiplatelet Agent in Thrombotic Stroke Patients

Tokyo, Japan (July 21, 2020) - Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the achievement of the primary endpoint in the Japan PRASTRO-III phase 3 study (hereafter, the study) of the antiplatelet agent, prasugrel hydrochloride (hereafter, prasugrel), in thrombotic stroke patients.

 

The study was carried out in a double-blind comparative manner to examine the efficacy and safety of prasugrel and clopidogrel in 234 thrombotic stroke patients with one or more risk factors for the recurrence of ischemic stroke.

 

The incidence  of cerebral cardiovascular events (such as ischemic stroke, myocardial infarction, and other vascular deaths) was lower in the prasugrel group than in the clopidogrel group, thus achieving the primary endpoint  in the study. Furthermore, no additional safety concerns were identified.

The results of the study will be announced in detail through future academic conferences and publications.

 

Daiichi Sankyo will continue efforts to provide new treatment options for thrombotic stroke patients.

 

Thrombotic stroke
Although ischemic stroke is caused by various conditions, thrombotic stroke is characterized by occlusion of cerebral blood vessels by platelet thrombi mainly due to arteriosclerosis.

 

About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders. For more information, please visit: www.daiichisankyo.com.